GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Wuhan Easy Diagnosis Biomedicine Co Ltd (SZSE:002932) » Definitions » 3-Year FCF Growth Rate

Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) 3-Year FCF Growth Rate : -7.80% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Wuhan Easy Diagnosis Biomedicine Co 3-Year FCF Growth Rate?

Wuhan Easy Diagnosis Biomedicine Co's Free Cash Flow per Share for the three months ended in Mar. 2024 was ¥-0.07.

During the past 12 months, Wuhan Easy Diagnosis Biomedicine Co's average Free Cash Flow per Share Growth Rate was -79.20% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -7.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Wuhan Easy Diagnosis Biomedicine Co was 542.00% per year. The lowest was -58.80% per year. And the median was -7.80% per year.


Competitive Comparison of Wuhan Easy Diagnosis Biomedicine Co's 3-Year FCF Growth Rate

For the Medical Devices subindustry, Wuhan Easy Diagnosis Biomedicine Co's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuhan Easy Diagnosis Biomedicine Co's 3-Year FCF Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Wuhan Easy Diagnosis Biomedicine Co's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Wuhan Easy Diagnosis Biomedicine Co's 3-Year FCF Growth Rate falls into.



Wuhan Easy Diagnosis Biomedicine Co 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Wuhan Easy Diagnosis Biomedicine Co  (SZSE:002932) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Wuhan Easy Diagnosis Biomedicine Co 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Wuhan Easy Diagnosis Biomedicine Co's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Business Description

Traded in Other Exchanges
N/A
Address
No. 1 Dongxin Road, 2 Floor, Building E, International Students Pioneer Park, Guandong Science and Technology Park, Donghu Development Zone, Hubei, Wuhan, CHN, 430075
Wuhan Easy Diagnosis Biomedicine Co Ltd is engaged in the research and development, production and sales of in vitro diagnostic reagents and supporting instruments and mobile ECG products. The company's product profile consists of Molecular diagnosis, Chemiluminescence, Blood gas analysis, and others. It also provides various other solutions such as Mingde Biomolecular Diagnostic Service Solution, Mingde Biothoracic Center Solution, POCT Solution, Remote ECG network construction solution, and others.
Executives
Wang Rui Directors, executives
Wang Jian Fei Director

Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Headlines

No Headlines